1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. North America Rare Neurological Disease Treatment Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. North America Rare Neurological Disease Treatment Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. North America Rare Neurological Disease Treatment Market Regional Analysis
6.2 North America Rare Neurological Disease Treatment Market Revenue 2017-2027 (US$ Million)
6.3 North America Rare Neurological Disease Treatment Market Forecast Analysis
7. North America Rare Neurological Disease Treatment Market Analysis – by Indication
7.1 Narcolepsy
- 7.1.1 Overview
- 7.1.2 Narcolepsy: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Amyotrophic Lateral Sclerosis
- 7.2.1 Overview
- 7.2.2 Amyotrophic Lateral Sclerosis: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.3 Alzheimer's Disease
- 7.3.1 Overview
- 7.3.2 Alzheimer's Disease: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.4 Multiple Sclerosis
- 7.4.1 Overview
- 7.4.2 Multiple Sclerosis: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.5 Spinal Muscular Atrophy
- 7.5.1 Overview
- 7.5.2 Spinal Muscular Atrophy: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.6 Duchenne Muscular Dystrophy
- 7.6.1 Overview
- 7.6.2 Duchenne Muscular Dystrophy: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.7 Other Indication
- 7.7.1 Overview
- 7.7.2 Other Indication: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. North America Rare Neurological Disease Treatment Market Analysis – by Drug Type
8.1 Organic Compounds
- 8.1.1 Overview
- 8.1.2 Organic Compounds: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Biologics
- 8.2.1 Overview
- 8.2.2 Biologics: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. North America Rare Neurological Disease Treatment Market Analysis – by Distribution Channel
9.1 Online Pharmacies
- 9.1.1 Overview
- 9.1.2 Online Pharmacies: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Hospital Pharmacies
- 9.2.1 Overview
- 9.2.2 Hospital Pharmacies: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Retail Pharmacies
- 9.3.1 Overview
- 9.3.2 Retail Pharmacies: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. North America Rare Neurological Disease Treatment Market Analysis – by Mode of Administration
10.1 Oral
- 10.1.1 Overview
- 10.1.2 Oral: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.2 Injectables
- 10.2.1 Overview
- 10.2.2 Injectables: North America Rare Neurological Disease Treatment Market – Revenue and Forecast, 2017-2027 (US$ Million)
11. North America Rare Neurological Disease Treatment Market – North America Analysis
11.1 Overview
11.2 North America
- 11.2.1 North America Rare Neurological Disease Treatment Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 11.2.1.1 North America Rare Neurological Disease Treatment Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 US:
North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.1.1 US: North America Rare Neurological Disease Treatment Market Breakdown, by Indication
- 11.2.1.1.2 US: North America Rare Neurological Disease Treatment Market Breakdown, by Drug Type
- 11.2.1.1.3 US: North America Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel
- 11.2.1.1.4 US: North America Rare Neurological Disease Treatment Market Breakdown, by Mode of Administration
- 11.2.1.2 Canada:
North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.2.1 Canada: North America Rare Neurological Disease Treatment Market Breakdown, by Indication
- 11.2.1.2.2 Canada: North America Rare Neurological Disease Treatment Market Breakdown, by Drug Type
- 11.2.1.2.3 Canada: North America Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel
- 11.2.1.2.4 Canada: North America Rare Neurological Disease Treatment Market Breakdown, by Mode of Administration
- 11.2.1.3 Mexico :
North America Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.3.1 Mexico : North America Rare Neurological Disease Treatment Market Breakdown, by Indication
- 11.2.1.3.2 Mexico : North America Rare Neurological Disease Treatment Market Breakdown, by Drug Type
- 11.2.1.3.3 Mexico : North America Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel
- 11.2.1.3.4 Mexico : North America Rare Neurological Disease Treatment Market Breakdown, by Mode of Administration
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Allergan plc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Bayer AG
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 GlaxoSmithKline plc.
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Johnson & Johnson Services Inc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Merck & Co. Inc.
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Novartis AG
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Pfizer Inc.
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Sanofi
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Teva Pharmaceutical Industries Ltd
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Takeda Pharmaceutical Company Limited
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations
Get Free Sample For North America Rare Neurological Disease Treatment Market
